REsiduAL rISk Under Intensive Lipid-lowering Therapy In Coronary Heart Disease — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

REsiduAL rISk Under Intensive Lipid-lowering Therapy In Coronary Heart Disease — Stella

Home/Coronary Heart Disease (CHD)/

View on ClinicalTrials.gov

Recruiting

Back to Coronary Heart Disease (CHD) trials

Trial locations(1 site)

China

Shanghai Zhongshan Hospital, Shanghai

Key details

Sponsor

Shanghai Zhongshan Hospital

Enrollment target

~900 participants

Started

July 2025

Primary completion

January 2027

Age range

18 Years – 75 Years

Last updated February 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.